Recently, Boston Scientific Corporation (NYSE:BSX) Announce the launch of a significant trial—AGENT DCB STANCETest.

This trial aims to use drug-coated balloons (DCB) and drug-eluting stents (DES) and/Or balloon angioplasty percutaneous coronary intervention (PCI) for head-to-head comparison, with patients having de novo (previously untreated) coronary artery lesions as the subjects. This study is a prospective, multi-center, open-label,1：1Randomized controlled trial, planned inclusion1600Multiple patients, the primary endpoint is defined as12Target lesion failure at the time of months.

Excluding AssessmentAgent DCBIn addition to its use in the treatment of small vessels from the beginning, the trial also focused on its application in patients with bifurcation and long lesions. Last year, Boston Scientific CorporationFDAApprovalAgent, making it the first drug-coated coronary balloon in the United States. Paclitaxel-coated balloons can replace traditional therapies such as balloon angioplasty, additional stent placement, or brachytherapy. Currently, the company provides its products in multiple international markets.AgentCommercial Services, Global Excellence100,000Patients have receivedAgentTreatment, and earlier this month also forDCBWinning Health Insurance.

Chief Medical Officer of Interventional Cardiology at Boston ScientificJanar SathananthanThe doctor said that this study will evaluateAgent DCBThe potential benefits for patients with new coronary artery lesions in specific anatomical features, positive results will support its expanded indications in the United States and help determine the optimal treatment strategy.